HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
2.000
-0.010 (-0.50%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.

It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis.

The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024.

HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

HeartSciences Inc.
HeartSciences logo
Country United States
Founded 2007
IPO Date Jun 15, 2022
Industry Medical Devices
Sector Healthcare
Employees 15
CEO Andrew Simpson

Contact Details

Address:
550 Reserve Street, Suite 360
Southlake, Texas 76092
United States
Phone 682 237 7781
Website heartsciences.com

Stock Details

Ticker Symbol HSCS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year May - April
Reporting Currency USD
IPO Price $4.25
CIK Code 0001468492
CUSIP Number 42254E104
ISIN Number US42254E3027
Employer ID 26-1344466
SIC Code 3842

Key Executives

Name Position
Andrew Simpson Chief Executive Officer, President and Chairman of the Board of Directors
Danielle Watson Chief Financial Officer and Treasurer

Latest SEC Filings

Date Type Title
Apr 17, 2026 QUALIF Filing
Apr 17, 2026 253G2 Acc-no: 0001493152-21-027927 (33 Act)
Apr 10, 2026 1-A POS Filing
Apr 3, 2026 8-K Current Report
Mar 19, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 17, 2026 DEF 14A Other definitive proxy statements
Mar 16, 2026 8-K Current Report
Mar 16, 2026 10-Q Quarterly Report
Mar 6, 2026 PRE 14A Other preliminary proxy statements
Jan 16, 2026 8-K Current Report